Long-term outcomes for leukemia patients linked to socioeconomic factors

Socioeconomic factors are directly associated with stem cell transplant rates and success in leukemia patients, according to a study from the Acute Leukemia Working Part of the European Group for Blood and Marrow Transplantation.

Sebastian Giebel, MD, of the Department of Clinical and Experimental Oncology at the Comprehensive Cancer Center of the Maria Sklowdowska-Curie Memorial Institute, and colleagues conducted a study to evaluate the association between the Human Development Index (HDI) and the rates and outcomes of patients with acute myeloid leukemia (AML). Involved in the study were 16,406 patients with AML who were treated with hematopoietic stem cell transplantation (HSCT). Researcher compared socioeconomic status with HSCT procedure rates and then analyzed long-term outcomes related to HSCT for a subgroup of 2,015 AML patients who had received an HLA-matched allogeneic HSCT.

The findings revealed that in Europe, the HDI was linked to both rates and results of HSCT for acute leukemia, with the strongest association related to the few countries in the highest HDI group. Researchers reported significant correlations between HDI and total HSCTs performed for AML patients.

Most significant in the study's findings was that the strongest associations were observed between transplant rates and scores related specifically to life expectancy and gross domestic product. Researchers suggested that not only purely economic conditions but also the organization of the health care and educational systems likely translate into availability of HSCT.

Results for patient outcomes revealed that transplants performed in countries in the highest HDI group were associated with significantly higher leukemia-free survival (68%), which resulted mainly from reduced risk of relapse, as compared with the other four HDI groups (56%, 59%, 63%, and 58%, respectively, in order of increasing HDI score)

"We believe there is still room for improvement in most European states to reach the outcomes achieved by the highest-HDI states, and identifying the factors that contribute to these differences is critical," said Dr. Giebel. "Our study was retrospective in nature, so we would encourage further prospective studies with detailed patient and procedural characteristics to help understand the true differences and design interventions to improve outcomes worldwide."

The study's findings were published in Blood (2010 Apr 15 [Epub ahead of print]).

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs